These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
940 related items for PubMed ID: 8137285
1. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Koyanagi N, Nagasu T, Fujita F, Watanabe T, Tsukahara K, Funahashi Y, Fujita M, Taguchi T, Yoshino H, Kitoh K. Cancer Res; 1994 Apr 01; 54(7):1702-6. PubMed ID: 8137285 [Abstract] [Full Text] [Related]
2. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152). Fujimoto K, Oka T, Morimoto M. Cancer Res; 1987 Mar 15; 47(6):1516-22. PubMed ID: 2434218 [Abstract] [Full Text] [Related]
3. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Yoshimatsu K, Yamaguchi A, Yoshino H, Koyanagi N, Kitoh K. Cancer Res; 1997 Aug 01; 57(15):3208-13. PubMed ID: 9242451 [Abstract] [Full Text] [Related]
4. Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity. McRipley RJ, Burns-Horwitz PE, Czerniak PM, Diamond RJ, Diamond MA, Miller JL, Page RJ, Dexter DL, Chen SF, Sun JH. Cancer Res; 1994 Jan 01; 54(1):159-64. PubMed ID: 8261436 [Abstract] [Full Text] [Related]
5. Antitumor activity and hematotoxicity of a new, substituted dihydrobenzoxazine, FK973, in mice. Shimomura K, Manda T, Mukumoto S, Masuda K, Nakamura T, Mizota T, Matsumoto S, Nishigaki F, Oku T, Mori J. Cancer Res; 1988 Mar 01; 48(5):1166-72. PubMed ID: 3342397 [Abstract] [Full Text] [Related]
7. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts. Gourdeau H, Genne P, Kadhim S, Bibeau L, Duchamp O, Ouellet F, deMuys JM, Bouffard DY, Attardo G. Cancer Chemother Pharmacol; 2002 Dec 01; 50(6):490-6. PubMed ID: 12451476 [Abstract] [Full Text] [Related]
8. Antitumor activity of TZT-1027, a novel dolastatin 10 derivative. Kobayashi M, Natsume T, Tamaoki S, Watanabe J, Asano H, Mikami T, Miyasaka K, Miyazaki K, Gondo M, Sakakibara K, Tsukagoshi S. Jpn J Cancer Res; 1997 Mar 01; 88(3):316-27. PubMed ID: 9140117 [Abstract] [Full Text] [Related]
9. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines. Tsuruo T, Yusa K, Sudo Y, Takamori R, Sugimoto Y. Cancer Res; 1989 Oct 15; 49(20):5537-42. PubMed ID: 2790778 [Abstract] [Full Text] [Related]
10. Preclinical antitumor activity of bizelesin in mice. Carter CA, Waud WR, Li LH, DeKoning TF, McGovren JP, Plowman J. Clin Cancer Res; 1996 Jul 15; 2(7):1143-9. PubMed ID: 9816280 [Abstract] [Full Text] [Related]
11. Antitumor activity of 7-N-[[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]]-mitomycin C. Morimoto M, Ashizawa T, Ohno H, Azuma M, Kobayashi E, Okabe M, Gomi K, Kono M, Saitoh Y, Kanda Y. Cancer Res; 1991 Jan 01; 51(1):110-5. PubMed ID: 1988076 [Abstract] [Full Text] [Related]
12. Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer. Utsugi T, Shibata J, Sugimoto Y, Aoyagi K, Wierzba K, Kobunai T, Terada T, Oh-hara T, Tsuruo T, Yamada Y. Cancer Res; 1996 Jun 15; 56(12):2809-14. PubMed ID: 8665518 [Abstract] [Full Text] [Related]
13. Antitumor activity and mechanism of action of the novel marine natural products mycalamide-A and -B and onnamide. Burres NS, Clement JJ. Cancer Res; 1989 Jun 01; 49(11):2935-40. PubMed ID: 2720652 [Abstract] [Full Text] [Related]
14. [Antitumor effect of a benzoylphenylurea derivative HO-221]. Nakajima T, Masuda H, Okamoto T, Watanabe M, Yokoyama K, Yamada N, Tsukagoshi S, Taguchi T. Gan To Kagaku Ryoho; 1990 Dec 01; 17(12):2353-9. PubMed ID: 2260871 [Abstract] [Full Text] [Related]
15. In vivo antitumor activity of S 16020-2, a new olivacine derivative. Guilbaud N, Kraus-Berthier L, Saint-Dizier D, Rouillon MH, Jan M, Burbridge M, Visalli M, Bisagni E, Pierré A, Atassi G. Cancer Chemother Pharmacol; 1996 Dec 01; 38(6):513-21. PubMed ID: 8823492 [Abstract] [Full Text] [Related]
16. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C. Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925 [Abstract] [Full Text] [Related]
17. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. Raynaud FI, Boxall FE, Goddard PM, Valenti M, Jones M, Murrer BA, Abrams M, Kelland LR. Clin Cancer Res; 1997 Nov 15; 3(11):2063-74. PubMed ID: 9815598 [Abstract] [Full Text] [Related]
18. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells. Watanabe M, Komeshima N, Nakajima S, Tsuruo T. Cancer Res; 1988 Dec 01; 48(23):6653-7. PubMed ID: 3180075 [Abstract] [Full Text] [Related]
19. Effect of E7010 on liver metastasis and life span of syngeneic C57BL/6 mice bearing orthotopically transplanted murine Colon 38 tumor. Funahashi Y, Koyanagi N, Kitoh K. Cancer Chemother Pharmacol; 2001 Dec 01; 47(2):179-84. PubMed ID: 11269745 [Abstract] [Full Text] [Related]
20. Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors. Guilbaud N, Kraus-Berthier L, Meyer-Losic F, Malivet V, Chacun C, Jan M, Tillequin F, Michel S, Koch M, Pfeiffer B, Atassi G, Hickman J, Pierré A. Clin Cancer Res; 2001 Aug 01; 7(8):2573-80. PubMed ID: 11489841 [Abstract] [Full Text] [Related] Page: [Next] [New Search]